… mutations and the poor response observed for exon 20 … gefitinib/erlotinib. Although most
EGFR-TKIs were not effective for exon 20 insertions, some patients benefited from treatment …

… The suboptimal response to ICI observed among … poor activity in patients with NSCLC with
driver alterations. A series of EGFR-mutant lung cancers previously reported poor responses …

… A good response to afatinib was evident in our patient who had lung … Lung cancer with
epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment …

… who received gefitinib as a previous EGFR-TKI treatment had a … as well as the use of
low-sensitivity detection methods (false … a partial response to previous EGFR-TKI treatment had a …

… subgroup of Non-Small Cell Lung Cancers (NSCLCs), that … treated with gefitinib [41],
though they may better respond to … Human epidermal growth factor receptor 2 (HER2) exon 20-…

… Epidermal growth factor receptor (EGFR) exon 20 insertion … with these EGFR mutations
respond to treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib, erlotinib…

… epidermal growth factor receptor 2 (ERBB2, HER-2) exon 20 … it is probably caused by the
low detection rate of CNV due to … induced upon treatment with erlotinib or gefitinib (39, 40) and …

… mutations were related to the sensitivity of NSCLC to gefitinib, … that predicted poor outcomes
and poor response to therapy [… or afatinib for the treatment of exon 20 insertion tumours have …

… -cell lung cancer to gefitinib. … response to treatment and epidermal growth factor receptor
tyrosine kinase inhibitors in patients with EGFR-mutant advanced non-small cell lung cancer. …

… There was no significant difference in the tumor response or … Epidermal growth factor
receptor (EGFR) mutations, mainly … to standard TKIs (erlotinib, gefitinib, afatinib), and their …